Farrukh T. Awan, MBBS, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia who were previously treated with a B-cell receptor pathway signaling inhibitor.
Farrukh T. Awan, MBBS, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.
Awan says treatment for CLL is rapidly evolving at this time and many patients are being exposed to kinase inhibitor treatments. He adds that when a patient fails a TKI treatment, further treatment is not well-defined. Data from the phase II trial shows that entospletinib is a well-tolerated compand in patients with CLL.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More